If you thought recent 500% gains on Dendreon (DNDN
) were impressive, you haven't seen anything. We're now talking about the possibility of coming close to... if not exceeding those gains this June 4-8, 2010 at the American Society of Clinical Oncology (ASCO
Here are some of the companies that Options Trading Pit, for one, is looking to trade over the next few weeks. Keep in mind that some will be played with stock only.
This is a list of stocks that should get considerable coverage at the conference.
Provectus (in the same industry as Dendreon) is focused on the development of cancer and psoriasis treatment based on the Rose Bengal compound. It's looking strong ahead of key clinical trials and ahead of the ASCO conference.
Here's what's really exciting. According to the company, "Rose Bengal is a red dye that was previously used to test for corneal scratches because it is preferentially absorbed by damaged cells. Provectus found that a highly specialized version of this dye is also absorbed in irregular or damaged cancerous cells."
"As the cancerous cells continue to take in more and more PV-10, they begin to rupture and eventually go into cell necrosis (death). The entire process also occurs without any radiation, which gives the treatment a substantial edge over existing treatments with side-effects."
Celldex Therapeutics (CLDX)
Partnered with Pfizer, Celldex's CDX-110 was developed for glioblastoma, a common and aggressive form of brain cancer. Shares of this stock are already running nicely ahead of the ASCO meeting.
Investors will get a first look at Phase III results at the ASCO meeting. This could be a very big catalyst for DCTH shares.
Here's more on the company from Adam Sharp:
The company announced positive clinical data for their proprietary liver cancer treatment system, The Delcath Percutaneous Hepatic Perfusion (PHP) device.
The PHP system works by first isolating the patient's liver from the rest of the circulatory system. This is accomplished using catheters and balloons, which are inserted via small incisions in the patient's neck and legs. Highly-concentrated doses of chemotherapy drugs are then delivered directly to the diseased organ.
After treatment, the blood is filtered and cleansed of potentially toxic drugs and returned to circulation.